Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned a consensus rating of “Hold” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is GBX 1,775 ($23.19).
HIK has been the topic of a number of analyst reports. Barclays reaffirmed an “underweight” rating on shares of Hikma Pharmaceuticals in a report on Monday, September 17th. Citigroup lifted their price objective on shares of Hikma Pharmaceuticals from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Peel Hunt reiterated an “add” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, October 3rd. Jefferies Financial Group upgraded Hikma Pharmaceuticals to a “buy” rating and lifted their target price for the stock from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a research note on Tuesday, November 27th. Finally, JPMorgan Chase & Co. lifted their target price on Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the stock a “neutral” rating in a research note on Tuesday, November 20th.
HIK traded down GBX 0.50 ($0.01) during mid-day trading on Friday, reaching GBX 1,594.50 ($20.83). 431,467 shares of the stock were exchanged, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 1 year low of GBX 814.20 ($10.64) and a 1 year high of GBX 2,346 ($30.65).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Article: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.